Kornimate/medical-research-clean huggingface dataset:
task-specific training for patients with acute exacerbation of copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: patients with chronic obstructive pulmonary disease (copd) experience a progressive deterioration in their quality of life. task-specific training is a type of approach focused on chronic patients that allows the acquisition of new skills or improvement of lost skills. the overall objective of this project is to evaluate the effectiveness of a task-specific training program during hospitalization of patients with acute exacerbation of copd. a randomized clinical trial will be conducted in patients hospitalized for copd. participants after signing informed consent will be randomized between the control group (standard treatment) and the intervention group (task-specific training program in addition to standard treatment). the task-specific training program is a multidisciplinary program divided into three blocks where specific tasks will be performed on symptom education, education of activities of daily living and improvement of physical capacity with the aim of reinforcing skills necessary for the self-management of copd patients in the short, medium and long term.


Eligibility criteria:
inclusion criteria: * patients hospitalized for acute exacerbation of copd. * over 18 years of age. * who wish to participate in the study. * who sign the informed consent form. exclusion criteria: * patients with inability to provide informed consent. * presence of psychiatric or cognitive disorders, organ failure, cancer and/or inability to cooperate. * patients who had experienced exacerbation of copd in the previous month were also excluded.
an intervention study to evaluate a website tailored to new dads to promote mental health

Conditions: Mental Health in Expectant First-time Fathers

Summary: the purpose of this study is to develop and pilot test healthydads.ca, a website for expectant first-time fathers who have known risk factors for depression.


Eligibility criteria:
inclusion criteria: * able to communicate in french or english * either married or cohabiting at the time of study entry * first child for both partners * have internet access * score \<12 on the edinburgh postnatal depression scale (epds) * not currently receiving psychotherapy from a health professional or on medication for a mental disorder * at least 1 risk factor for depression if they score \< 6 on the epds: a)history of depression, b) elevated anxiety or c) couple discord exclusion criteria: * suicidal ideation or intent * physical condition precluding participation in exercise
prognosis predictors for heart failure

Conditions: Heart Failure; Rehabilitation; Morality; Hospitalization; Life Quality

Summary: this study is looking for the predictors of the survival or rehospitalization of patients with heart failure with reduced ejection fraction. participants who are discharged from an acute heart failure hospitalization are enrolled.

this study is looking for the predictors of the survival or rehospitalization of patients with heart failure with reduced ejection fraction. participants who are discharged from an acute heart failure hospitalization are enrolled. the prognostic factors provide information about the treatment of this disease in the future. this study is a retrospective observational study. investigators will collect data from may 2014 to july 2019 in the heart failure center of kaohsiung chang gung memorial hospital. a follow-up is conducted at the kaohsiung hf center until august 2020. investigators want to know whether the risk factors such as atrial fibrillation, diabetes, nephropathy, and some biochemical indexes can be an index that predicts future survival or rehospitalization of these patients. besides, investigators will also explore the cardiac rehabilitation can also effectively improve the survival rate of such patients.

Eligibility criteria:
inclusion criteria: * inpatient, age \>= 20 years old, male or female * patient with heart failure with a reduced ejection fraction and discharged alive from the hospital * received heart failure disease management program exclusion criteria: * estimated survival time \< 6 months * long-term bedridden for more than 3 months * cannot tolerance exercise test due to muscular-skeletal disorder * cannot co-operate all functional studies * ventilator dependent * terminal heart status * the family reject to participate in this project

Keywords: cardiac rehabilitation multidisciplinary program heart failure mortality renin-angiotensin-aldosterone system
characteristics of patient population with endometriosis

Conditions: Endometriosis

Summary: the purpose of this study is to collect and analyze data on the characteristics of women who are seeking treatment for endometriosis, suspected endometriosis, pain and/or infertility as part of their standard medical care. data collected will contribute to the development of guidelines for the surgical management of endometriosis. in addition, specimens will be collected for future testing regarding diagnosing, and/or staging of endometriosis, or suspected endometriosis, pain and infertility.

patients seen at saint louis university center for endometriosis (which has offices locations at st. mary's, st. luke's and the slu-umg clinic - all of which are in the slu epic system), and operated on for endometriosis, suspected endometriosis, pain and/or infertility at st. mary's hospital (only). a preoperative questionnaire will be provided to the subject. questions from the survey include information on baseline demographics, severity and type of pain, and previous medical and surgical history. operative data will also be collected and analyzed. a post-operative questionnaire will be administered to the participants at 6 months, and then at regular yearly intervals after the surgery by a secure on-line process using the redcap software. improvement in quality of life and pain scores will be analyzed. specimens will also be collected and stored for future testing regarding diagnosing, and/or staging of endometriosis, suspected endometriosis, pain and infertility.

Eligibility criteria:
inclusion criteria: * female patients * 13-55 years of age * anyone seen at the center for endometriosis exclusion criteria: * prior bilateral salpingo-oophorectomy * post natural menopause * significant mental or chronic systemic illness that might confound pain assessment or the inability to complete the study.
reasons for prehospital delay in patients with acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: ischemic stroke is the leading cause of acquired disability among adults, and one of the main causes of death. in switzerland, the approved time window for stroke treatment with intravenous thrombolysis after symptom onset is 4.5 h. even within the 4.5 h time-window, however, the benefit of treatment strongly decreases as time passes. moreover, only around 10% patients receive thrombolytic treatment, since patients with stroke arrive too late to the hospital (prehospital delay). despite efforts to educate the community on the symptom of stroke, prehospital delay did not decrease over time, and the reasons remain incompletely understood. prehospital delay reduces the proportion of patients with ischemic stroke treated with thrombolysis, and reduces the odds of favorable outcome among the minority treated with thrombolysis. this prospective cohort study aims at understanding the causes of prehospital delay among patients with acute ischemic stroke. trained study-nurses will interview, at the bedside, patients and proxies along a standardized questionnaire on prehospital delay. avoiding modificables causes of prehospital delay may increase the thrombolysis rate and improve outcomes after stroke.


Eligibility criteria:
inclusion criteria: * patients with an acute ischemic stroke hospitalized in the stroke center of the university hospital basel. exclusion criteria: * patient not able to answer the in-person, bedside questionnaire asked by a trained study nurse. * patient not willing to participate to the study
the added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue

Conditions: Physical and Rehabilitation Medicine

Summary: introduction: multiple sclerosis (ms) has a wide range of physiological and neuropsychological symptoms. over 75% of ms patients complain about fatigue, which for many is one of their most debilitating symptoms, having a substantial impact on their quality of life and ability to carry out day-to-day tasks. previous investigations on the effectiveness of different types of psychotherapy on ms fatigue are extremely limited. the aim of this study was to investigate the added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue

patients with fatigue symptoms (score of ≥5 on fatigue scale) will be randomly assigned into experimental (n=30) and control (n=30) groups. the subjects in the experimental group will receive eight 50-minute sessions of weekly cognitive behavior therapy based on van kessel's model in addition cognition-targeted exercise program , whereas the patients in the control group will receive eight 50-minute sessions of weekly cbt in addition to standardized physiotherapy program . a standardized program of physiotherapy exercises will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions. this exercise program is reflective of the general exercises typically undertaken within routine clinical practice.

Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis by a neurologist which incorporate clinical features with magnetic resonance scanning. * being within normal or average dysfunction and excluding those scoring ≤6 in the expanded disability status scale (edss); * being identified as a case level of fatigue; fatigue score of 4 or greater on the fatigue scale (fs); exclusion criteria: * patients with any serious psychological disorders (including psychotic disorders or active substance abuse), or those with any chronic illness that may be contributing to fatigue were excluded.

Keywords: randomized controlled trial multiple sclerosis fatigue cognitive behavioral therapy exercise
safety, tolerability and pk of pxl770 in healthy male subjects

Conditions: Metabolic Disease

Summary: pxl770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (ampk) being developed by poxel s.a. for the treatment of type 2 diabetes mellitus (t2dm). in part a of this study, we'll test the safety, tolerability and pharmacokinetics (pk) of repeated doses. in part b, we'll co-administer pxl770 and rosuvastatin (a hmg-coa reductase inhibitor) to assess any drug-drug interaction.


Eligibility criteria:
inclusion criteria: * male subjects deemed healthy on the basis of a clinical history, physical examination, ecg, vital signs, and laboratory tests of blood and urine * body mass index in the range 18.5-29.9 kg/m² * body weight at least 60 kg * willing to use reliable contraception * able to give fully informed written consent. exclusion criteria: * pregnant or lactating woman, or sexually active woman of child-bearing potential not using reliable contraception * clinically relevant abnormal findings at the screening assessment * clinically significant vital signs outside the acceptable range at screening * clinically relevant abnormal medical history, surgery or concurrent medical condition * acute or chronic illness * estimated glomerular filtration rate less than 80 ml/min/1.73 m2 * severe adverse reaction to any drug or sensitivity to the trial medication or its components * significant food allergy; vegetarian or vegan * participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 ml blood, within the 3 months before first dose of trial medication * drug or alcohol abuse * smoking of more than 5 cigarettes daily * possibility that subject will not cooperate * positive test for hepatitis b \& c, hiv * objection by a general practitioner
survivorship care planning in improving quality of life in survivors of ovarian cancer

Conditions: Cancer Survivor; Stage IA Ovarian Epithelial Cancer; Stage IB Ovarian Epithelial Cancer; Stage IC Ovarian Epithelial Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIC Ovarian Epithelial Cancer

Summary: this pilot clinical trial studies survivorship care planning in supporting quality of life in ovarian cancer survivors following primary treatment. survivorship care plans have the potential to empower patients and provide them with a plan of care following treatments. survivorship care planning may support patient's overall well-being and quality of life after treatment of ovarian cancer.

primary objectives: i. to assess the feasibility and acceptability of survivorship care planning (scp) in ovarian cancer. secondary objectives: i. to develop the infrastructure and strategy for a larger comparative intervention study (national cancer institute \[nci\] r01). outline: participants are assigned to 1 of 2 arms. arm i: participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists. arm ii: participants complete survivorship care planning in close collaboration with treating oncologists. after completion of study treatment, participants are followed up at 2 months.

Eligibility criteria:
inclusion criteria: * diagnosis of stage i, ii, or iii ovarian cancer * ability to read or understand english * all subjects must have the ability to understand and the willingness to sign a written informed consent exclusion criteria: * subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
covid-19 prep hcw hcq study

Conditions: COVID-19

Summary: off label study to evaluate the efficacy of hcq for pre-exposure prophylaxis (prep) to prevent severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection. 350 participants will be assigned to the group that takes hcq or the group that opts to not take the study medication. participants will be nyulh hcw at high risk for occupational exposure to sars-cov-2. study timepoints will include screening/enrollment, 30 day, 60 day, and 90 day visits. questionnaires, and dbs will be collected in all timepoints.

hydroxychloroquine (hcq) is licensed for the chemoprophylaxis and treatment of malaria and as a disease modifying antirheumatic drug. it has a long history of being safe and well tolerated at typical doses. hcq has antiviral activity in vitro against coronaviruses, and specifically covid-19. this study is designed to evaluate the efficacy of hydroxychloroquine (hcq) for pre exposure prophylaxis (prep) to prevent severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection among health care workers at high risk of occupational exposure to sars-cov-2 compared to the eligible cohort that declines treatment.

Eligibility criteria:
inclusion criteria for group a and b * men or women ages ≥18 years nyulh health care worker who meets one of the following criteria 1. involved in an aerosol generating procedure (nasopharyngeal specimen collection, tracheal intubation, nebulizer treatment, open airway suctioning, collection of sputum, tracheostomy, bronchoscopy, cpr) on a confirmed covid-19 patient while wearing ppe 2. direct bedside care of confirmed covid-19 patient while wearing ppe for 3 or more shifts in a 7 day period 3. direct care of puis in the ed or other inpatient unit while wearing ppe for 3 or more shifts in a 7 day period * willing and able to provide informed consent exclusion criteria for group a only : * known hypersensitivity to hydroxychloroquine or chloroquine * known diagnosis of covid-19 * concomitant use of 1. amiodarone 2. digoxin 3. flecainide 4. procainamide 5. propafenone * history of torsades de pontes * history of retinal disease * known chronic kidney disease ≥ stage 4 * congenital prolonged qtc interval syndrome (jervell and lange-nielsen syndrome, romano-ward syndrome)
the association between delivered oxygen and cerebral impact during the use of cardiopulmonary bypass.

Conditions: Cardiac; Arteriosclerosis; Aortic Valve Disease

Summary: investigating the connection between delivered oxygen index and cerebral impact with cox (cerebral oximetry index) och cerebral injury markers during the routine use of cardiopulmonary bypass.

the research subjects are to be treated with cpb with according to local standards (perfusion index 2.4 x body surface area). while measuring impact on cerebral autoregulation with the aid of near infrared spectroscopy (nirs) and brain injury markers in blood, research subjects depending on initial hemoglobin value, will divide into two subgroups: one with do2i of \>280 ml/min/m2, and one with do2i of \<280 ml/min/m2. do2i will during cpb be calculated using the patient data monitoring system metavision. with a correlation analysis between nirs and map (mean arterial pressure) a cox (cerebral oxymetry index) r-value can indicate impact on cerebral autoregulation with values \>0.3 - 0.5 during use of cpb 4. brain injury markers (tau, glial fibrillary acidic protein (gfap), neurospecific enolase (nse)) are collected during 5 occasions during the first 24 hours and then once per day for 4 days, as well as markers for aki (s-creatinine) in some extent. registrations during the intensive care regarding delirium, stroke or other neurological impact will also be included in the study.

Eligibility criteria:
inclusion criteria: * patients scheduled for cabg and/or avr exclusion criteria: * former diagnosed neurological insults, carotid stenosis
assessment of nsaid-treated patients adherence to co-prescribed proton pump inhibitor (ppi)

Conditions: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis

Summary: the primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to ppi, when prescribed as prevention of nsaid associated gi ulcers to patients prescribed a nsaid. patients included have osteoarthritis, rheumatoid arthritis or ankylosing spondylitis. adherence will be assessed by patient questionnaires.

cross-sectional, observational real life study on nsaids treated patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis: assessment of patient adherence to ppi treatment

Eligibility criteria:
inclusion criteria: * confirmed diagnosis (documented in the medical record) of oa, ra or as * prescription of oral nsaid treatment for oa, ra or as, where low dose is not sufficient * prescription of ppi for prevention of nsaid associated gi ulcers, with instruction to take ppi same day as when taking nsaid. exclusion criteria: * participating in any clinical trial involving ppi or nsaid * patients prescribed ppi as acute treatment of gi events or symptoms within 8 weeks * inability to complete pros

Keywords: osteoarthritis rheumatoid arthritis ankylosing spondylitis
predictors of intracranial hemorrhage in ards patients on ecmo

Conditions: ARDS, Human; Extracorporeal Membrane Oxygenation Complication

Summary: intracranial hemorrhage is is a rare, but critical incident in patients with acute lung failure undergoing ecmo therapy. predictors of intracranial hemorrhage are yet to be defined to identify patients at (high) risk. this retrospective analysis investigates the predictive value and validity of parameters and specific risk factors of critically ill ards patients treated with ecmo.


Eligibility criteria:
inclusion criteria: * ards following berlin definition (mild, moderate, severe) * ecmo therapy (veno-venous cannulation) exclusion criteria: * ecmo, other than vv * ich at initiation of ecmo * no cerebral ct scan at any time
protocol design for evaluating the immunity of bivalve fluids from anodonta cygnea in sars and covid-19

Conditions: Coronavirus Infections; Coronavirus Sars-Associated; SARS (Severe Acute Respiratory Syndrome); COVID-19

Summary: the present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human sars and covid-19 lineage infection. the methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary sars and covid-19 infected persons with an integrative diagnosis by a computational mora®nova apparatus to access the basal and experimental human physiological parameters.

a deep and consistent study will be developed with an increase in the human sampling for better understanding the intervention efficacy of this intelligence medicine integrator, the mora® nova method. these in silico experiments when associated with the bioresonance frequencies from stimulated hemolymph compounds of the freshwater bivalve a. cygnea, may lead us to expect high plasticity and immunological potential. obviously, additional in vitro studies in future, with adequate culture cell lineages in different conditions and with bioresonance treatment by mora® nova method, should also be accomplished with hemolymph/plasma interference to confirm the pertinence, and the real efficacy on sars / covid-19 infection as well as to clarify the respective biological mechanisms. in addition, to analyze and evaluate any specific bioactive compound from the induced hemolymph condition needs molecular experiments which can give deep structural information concerning any efficient molecule against the sars / covid-19 virus lineage and respective mutants. effectively, according to current scientific opinion, the virus mutation phenomenon leads to great and problematic difficulty for maintaining the collective and human global immunization. in this case, the present mora methodology offers a very functional, dynamic, and efficient process when combined with a biological model, as the bivalve a. cygnea, with high plasticity and eventual molecular reconstructive adaptation. this mora procedure can extend to other immune-depressive diseases namely cancer, rheumatoid arthritis, and neurodegenerative diseases combining with respective stimulated bivalve fluids. it suggests opening a promising future perspective when applied to large human sampling as well as with in vitro cellular assays. in addition, to explore this research with in vitro cell cultures and to do the characterization and the effects from bio-compounds on similar diseases is our close objective.

Eligibility criteria:
inclusion criteria: * subjects with normal physiological state or any kind of comorbidity exclusion criteria: * subjects in highly critical health state
impact of hysterectomy on quality of life and urethral length

Conditions: Fibroid Uterus; Urethral Diseases; Sex Disorder

Summary: to establish the impact of hysterectomy on sexual function, urethral length and quality of life

the investigators evaluate impact of total hysterectomy (abdominal, by laparoscopy and vaginal) and supracervical hysterectomy (abdominal and by laparoscopy) on quality of life, sexual function, urethral length and urinary incontinence. the patients fulfill questionnaires (udi 6, iiq7, fsfi and iciq) before operation and 6 months after. additionally the investigators measure urethral length before procedure and 6 months after.

Eligibility criteria:
inclusion criteria: * patients qualified to hysterectomy due to benign condition exclusion criteria: * serious health condition * previous vaginal operations

Keywords: quality of life urethral length sexual function